Skip to main content
. 2016 Dec 7;6(2):e1252895. doi: 10.1080/2162402X.2016.1252895

Figure 4.

Figure 4.

NLM peptide induced stronger T cell cytotoxicity against WT1+ leukemia cells in the context of HLA-A*02:01 molecule. CD3T cells from a donor who is HLA-A*02:01 homozygous were stimulated with analog NLM peptide (A), native NQM peptide (B) and NYM peptide (C) for five rounds and the cytotoxicity was measured against WT1+ HLA-A*02:01+ leukemia cells 697 and BV173 and WT1+ HLA-A*02:01− leukemia cell line HL-60. The T cells also lysed AML blasts from a patient who is WT1+ HLA-A*02:01+ (blue line) and IFN-gamma treatment further enhanced the cytotoxicity (red line). No killing was observed against the AML blasts from a patient who is WT1+, but HLA-A*02:01 negative (green line: untreated and purple line: with IFN-gamma) (D). Each data point represents the mean from triplicate micro-well cultures. Data represent results from seven experiments from three donors in panels A, B and C, and three experiments from three pairs of samples from AML patients.